Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Novartis ends ALS program after phase 2 flop, adding to R&D woes

Novartis ends ALS program after phase 2 flop, adding to R&D woes

  • September 16, 2026

Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis program after flunking a phase 2 trial.

Leave A Comment

Fields (*) Mark are Required